A controversy is swirling at a Texas university. The trigger? A flowchart. On Dec. 1, the new chancellor of the Texas Tech University system sent professors a diagram laying out a chain of approval ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since Aristotle, who wrote that humanity was “the animal that has language.” ...
The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Hosted on MSN
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback